Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled the biotech's stock to a staggering 714% surge since the completion of the drug's Phase 1 trial on March ...
motleyfoolusx:vktx
Viking Therapeutics (NASDAQ: VKTX) has been flying on all cylinders since the beginning of the year. The company's shares are up 246% due to excellent clinical progress. It's not rare for smaller biotechs to see their stock prices skyrocket relatively quickly, but many eventually give up most, if not ...
motleyfoolusx:vktx
Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain? Three Motley Fool contributors think they've found magnificent stocks that could double or more by 2030. Here's why they picked CRISPR Therapeutics ...
motleyfoolusx:llyusx:vktxusx:crsp
CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the clinical or regulatory front. These relatively small drugmakers look highly promising thanks to their ...
motleyfoolusx:vktxusx:crsp
One of the hottest areas of the pharmaceutical industry right now is the weight loss treatment space. Novo Nordisk and Eli Lilly have been the primary innovators. Their groundbreaking glucagon-like peptide-1 (GLP-1) agonists are in high demand for both diabetes and weight loss, marketed under names including ...
motleyfoolusx:vktx
Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX) are both biotechs developing treatments for metabolic diseases, so it's to be expected that they have more than a few things in common. But investors are probably interested most in the fact that shares of both companies are ...
motleyfoolusx:vktxusx:mdgl
Are we witnessing the rise of a new biotech giant? A few weeks ago, Viking Therapeutics (NASDAQ: VKTX) grabbed headlines when it reported positive results from a phase 2 clinical trial for VK2735, a potential anti-obesity medicine. That was quite an accomplishment. Many drugmakers, including most of ...
motleyfoolusx:vktx
There aren't many hotter stocks on the market right now than Viking Therapeutics (NASDAQ: VKTX). Shares of the biopharmaceutical company have skyrocketed around 340% so far this year. However, those impressive gains might be just a start for Viking. The company should have plenty of potential catalysts ...
motleyfoolusx:vktx
Investors looking for stocks that can make dramatic gains in a short time frame might want to turn their attention to the biopharmaceutical industry. Shares of Viking Therapeutics (NASDAQ: VKTX) have already risen more than four-fold this year. Despite Viking's rapid ascent Oppenheimer analyst, Jay Olson ...
motleyfoolusx:vktx
Viking Therapeutics (NASDAQ: VKTX) has emerged this year as a formidable contender in the increasingly popular anti-obesity market. While it doesn't have an approved drug fighting for market share just yet, investors are incredibly bullish on the prospects for VK2735, which has been demonstrating encouraging ...
motleyfoolusx:vktx
Relatively small biotechs can see their shares soar -- sometimes significantly -- following positive clinical or regulatory news. That's what has happened this year to Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, with its stock price up by nearly 300% since January. Madrigal Pharmaceuticals ...
motleyfoolusx:vktxusx:mdgl
Investors are very eager to buy into biotechs and pharmaceuticals that are involved in developing weight-loss medications. This is why Viking Therapeutics (NASDAQ: VKTX), which has such a drug in its pipeline, has been a popular stock lately. Over the past few trading days, Viking has made many investors ...
motleyfoolusx:vktx
Shares of Viking Therapeutics (NASDAQ: VKTX) had skyrocketed by 25% as of 11:08 a.m. ET on Tuesday. That big gain came after the company announced results from a phase 1 clinical study evaluating an oral formulation of its experimental obesity drug VK2735. Viking reported that patients in the study who ...
motleyfoolusx:vktx
When it comes to rising stars in biotech, Viking Therapeutics (NASDAQ: VKTX) should probably be one of the first businesses to come to mind today. The company doesn't yet have any sales revenue, but its pipeline of metabolic disease drugs has more than one highly promising project in the works, and investors ...
motleyfoolusx:vktx
There's no shortage of hype and excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock these days. The company has a promising weight loss drug candidate in its pipeline at a time when many healthcare businesses are eager to get a piece of that massive market. This year alone, shares of Viking ...
motleyfoolusx:vktx
Viking Therapeutics (NASDAQ: VKTX) now ranks among the hottest biotech stocks on the market. The company's announcement in February of positive results from its phase 2 study of experimental weight loss drug VK2735 provided a huge catalyst. The future for Viking appears to be bright. But where will this ...
motleyfoolusx:vktx
